Differences

This shows you the differences between two versions of the page.

--- chapter_17 [2025/05/16 21:50] – [CRISPR/Cas9] mike
+++ chapter_17 [2025/05/16 21:52] (current) – [Viral vectors] mike
@@ Line 81: / Line 81: @@
   * A third plasmid that expresses the essential E2A, E4, and VA genes from adenovirus (green in Fig. {{ref>Fig6}})
-You would then introduce all three plasmids into cultured cells (such as HEK293 cells, a human embryonic kidney cell line). The purple and green plasmids, together with the HEK293 host cell genome, provide all the proteins needed to replicate and package newly replicated viral ssDNAs. However, only DNA with ITRs will be packaged. This means that the plasmids containing AAV and adenoviruses will not be packaged (they won't even be replicated) - only the ssDNA with the ITRs, and therefore your trangene, will be packaged into new viral capsids. You can harvest the rAAVs from the media of the HEK293 cell culture.
+You would then introduce all three plasmids into cultured cells (such as HEK293 cells, a human embryonic kidney cell line). The purple and green plasmids, together with the HEK293 host cell genome, provide all the proteins needed to replicate and package newly replicated viral ssDNAs. However, only DNA with ITRs will be packaged. This means that the plasmids containing AAV and adenoviruses will not be packaged (they won't even be replicated) - only the ssDNA with the ITRs, and therefore your transgene, will be packaged into new viral capsids. You can harvest the rAAVs from the media of the HEK293 cell culture.
 <figure Fig6>
@@ Line 103: / Line 103: @@
 </columns>
 <caption>
-Some example of AAV serotypes (variants) with different tissue targeting specificity (tropism). Adapted from Naso et al. (2017) BioDrugs 31(4): 317-334 https://doi.org/10.1007%2Fs40259-017-0234-5. Liscensing: [[http://creativecommons.org/licenses/by-nc/4.0/|CC BY-NC-4.0]].
+Some example of AAV serotypes (variants) with different tissue targeting specificity (tropism). Adapted from Naso et al. (2017) BioDrugs 31(4): 317-334 https://doi.org/10.1007%2Fs40259-017-0234-5. Licensing: [[http://creativecommons.org/licenses/by-nc/4.0/|CC BY-NC-4.0]].
 </caption>
 </table>